Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | SDCBP | O00560 | 1/20 | 0.31 |
| ▸ | SDC2 | P34741 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27042665 | 1.00 | RAB9A (0.41) | RAB9AACESDCBPSDC2SLC7A5 | |
| SCHEMBL3360548 | 0.89 | RAB9A (0.39) | RAB9AACESDCBPSDC2 | |
| SCHEMBL30728811 | 0.84 | LMNA (0.33) | ACE | |
| SCHEMBL22122383 | 0.77 | RAB9A (0.35) | RAB9A | |
| SCHEMBL22122385 | 0.77 | RAB9A (0.35) | RAB9A | |
| SCHEMBL24568171 | 0.74 | PIK3CD (0.34) | PIK3CD | |
| SCHEMBL28424905 | 0.74 | PIK3CD (0.34) | PIK3CD | |
| SCHEMBL8164184 | 0.74 | ACE (0.36) | RAB9AACE | |
| SCHEMBL1106520 | 0.73 | PIK3CD (0.36) | MAPTPIK3CD | |
| SCHEMBL13541145 | 0.72 | DPP4 (0.35) | RAB9AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268894-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4558507-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| CN-119585284-A | Macrocyclic compounds for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2025-03-07 | — | — | CN | disclosed |
| WO-2024017859-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024017859-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| US-7279582-B2 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2007-10-09 | — | — | US | disclosed |
| US-20030100755-A1 | Retroviral protease inhibiting compounds | ABBVIE INC. | 2003-05-29 | — | — | US | disclosed |
| EP-1295874-A2 | Retroviral protease inhibiting compounds | Abbott Laboratories (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-0882024-B1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-1170289-A2 | Retroviral protease inhibiting compounds | Abbott Laboratories (US) | 2002-01-09 | — | — | EP | disclosed |
| US-6313296-B1 | 2-PYRROLIDINONE-1-ACETIC ACID DERIVATIVES; VIRICIDES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV); ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) TREATMENT | ABBOTT LABORATORIES | 2001-11-06 | — | — | US | disclosed |
| US-5914332-A | NOVEL COMPOUNDS FOR USE AS HIV PROTEASE INHIBITORS IN TREATING HIV AND AIDS | ABBOTT LABORATORIES (US) | 1999-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100755-A1 | Retroviral protease inhibiting compounds | SERPINB1, PREP, TMPRSS15 | RAB9A 1974/4885ACE 48/4885SDCBP 2460/4885 |
| US-20250268894-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2, CCNA1 | RAB9A 911/4885ACE 1858/4885SDCBP 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.